NMIBCNCT06810141
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
A study testing rMBCG in people with NMIBC, run by ImmunityBio, Inc. at 66 sites in United States.
Trial summary
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are ineligible to participate in a clinical trial using rMBCG, or for other reasons cannot… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- NMIBC
- What is being tested?
- rMBCG
- How many people
- Not given
- Where
- 66 sitesUnited States
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- Adult, Older adult
Who may be able to join
- Participants must meet the inclusion criteria and contraindications determined by the standards of their institution per the TICE BCG label. In BCG naïve subjects with NMIBC, enrollment should occur only if TICE BCG is unavailable.
Who cannot join
None listed.
Trial locations and contacts
66 sites in 1 country.
66 sites in 1 country
United States66 sites
- Available
Albany Urology Clinic and Surgery Center
Albany, Georgia, 31707
Michael Monahan, DO
- Available
Albany Medical College
Albany, New York, 12208
Laura Davey, 518-262-8579, AMCUrologyresearch@amc.edu
Adrien Bernstein, MD
- Available
Emory University
Atlanta, Georgia, 30322
Shreyas Joshi
- Available
Georgia Urology
Atlanta, Georgia, 30328
Caroline Branch, 470-365-7728, CBranch@gaurology.com
Daniel Canter, MD
- Available
Urology of Indiana
Carmel, Indiana, 46032
Chad Reichard, MD
- Available
Erlanger Health, Inc.
Chattanooga, Tennessee, 37403
Lorraine Christensen, 423-778-3902, lorraine.christensen@erlanger.org
Amar Singh
- Available
Cleveland Clinic
Cleveland, Ohio, 44195
Lauren Grimm, grimml@ccf.org
Laura Bukavina, MD
- Available
North Idaho Urology, PLLC
Coeur d'Alene, Idaho, 83814
Nicole Fox, 208-667-0621, nfox@niurology.com
Chad Peterson, MD
- Available
Louisiana Healthcare Associates
Covington, Louisiana, 70433
985-892-6811
Sunil Purohit, MD
- Available
Danville Urologic Clinic
Danville, Virginia, 24541
Renee Pickrel, 434-792-1433, rpickrel@southsidedocs.com
Joseph Carbone, MD
- Available
Advent Health Porter
Denver, Colorado, 80210
Jenni Freed, Jenni.Freed@AdventHealth.com
John Tillet, MD
- Available
Karmanos Cancer Institute
Detroit, Michigan, 48201
Brenda Dickow, 313-576-9372, dickowb@karmanos.org
Kevin Ginsburg, MD
- Available
Essentia Health - Duluth Clinic
Duluth, Minnesota, 55805
Bret Friday, MD, PhD
- Available
Rio Grande Urology
El Paso, Texas, 79912
Jesus Herrera-Murillo, MD
- Available
Augusta Urology Associates, LLC
Evans, Georgia, 30809
Michelle Legrand, 706-722-0705, mlegrand@augustaurology.com
Henry N Goodwin, MD
- Available
Potomac Urology
Fairfax, Virginia, 22033
Aseem Malhotra, MD
- Available
Broward Urology Center
Fort Lauderdale, Florida, 33316
954-463-6408
Eric Chenven, MD
- Available
Genesis Care
Fort Myers, Florida, 33908
Brian Schwartz
- Available
Cleveland Clinic
Garfield Heights, Ohio, 44125
Kailash Kedia, MD
- Available
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, 38138
Linda Brantley, 901-683-0055
Bradley G Somer, MD
- Available
US Urology Partners - Carmel
Greenwood, Indiana, 46143
Chad Reichard, MD
- Available
University Urology of NJ
Hamilton, New Jersey, 08690
Mukaram Gazi
- Available
Urology Centers of Alabama
Homewood, Alabama, 35209
Meredith Sharpton, 205-930-0902, msharpton@urologyal.com
Austin Lutz, MD
- Available
Hawaii Cancer Care
Honolulu, Hawaii, 96813
Isobel Webster, 808-524-6115 ext. 519, isobel.webster@aoncology.com
David Tamura, MD
- Available
Island Urology Oahu
Honolulu, Hawaii, 96813
808-536-2306
Sergei Tikhonenkov, MD
- Available
Mayo Clinic
Jacksonville, Florida, 32224
Cristina Watson, 904-953-9887, watson.cristina@mayo.edu
Timothy Lyon, MD
- Available
First Urology, P.S.C
Jeffersonville, Indiana, 47130
Ryan Malone
- Available
The University of Tennessee Medical Center
Knoxville, Tennessee, 37920
Lauren Simpson, 865-305-9254, lsimpson@utmck.edu
James Bienvenu, MD
- Available
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Daisey Perez, 858-822-5354, daperez@health.ucsd.edu
Aditya Bagrodia, MD
- Available
Comprehensive Urologic Care
Lake Barrington, Illinois, 60010
Sunny Sian, ssian@compurocare.com
Ning Wu, MD
- Available
Cohen Urology
Lake Worth, Florida, 33449
Aviram Assidon
- Available
Advanced Urology, Center for Robotic Surgery
Leland, North Carolina, 28451
Sandy Pyland, 910-641-8655, spyland@crhealthcare.org
Roc A McCarthy, MD
- Available
Kansas City Urology Care, PA
Lenexa, Kansas, 66214
David Bock
- Available
Cancer Partners of Nebraska
Lincoln, Nebraska, 68156
Antonio Beltran, MD
- Available
USC/ Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Irene Qazi, 323-865-3081, irene.qazi@med.usc.edu
Siamak Daneshmand, MD
- Available
Advance Urology Associates Enterprises/ HLP Urology Associates
Manasquan, New Jersey, 08736
Mark Perlmetter, MD
- Available
The Urology Clinic
Meridian, Idaho, 83642
Laura Pazmino, 208-991-6232, pazmino.rn@theurologyclinic.net
Michael Taylor, MD
- Available
Allina Health Cancer Institute- Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407
Payton Kaiser, 320-262-0594, payton.kaisar@allina.com
Badrinath Konety, MD
- Available
University Urology
Mobile, Alabama, 36606
Christopher Keel, DO
- Available
Urology Associates
Mobile, Alabama, 36607
Ted Klein
- Available
Garden State Urology
Morristown, New Jersey, 07960
Nathalia Salazar, 973-539-0333, necheverra@gsunj.com
David Taylor, MD
- Available
Urology Associates of Charleston
Mt. Pleasant, South Carolina, 29464
Diane Hader, 843-884-8045
Jonathan Donaldson, MD
- Available
Urology Center of Southern California
Murrieta, California, 92563
Laura Guerrero, 760-207-2560, lguerrero@folioclinicalresearch.com
Madhumitha Reddy, MD
- Available
AUC Urologists, LLC
Myrtle Beach, South Carolina, 29572
843-839-1679
Neal D Shore, MD
- Available
NRMC Urology Associates
Natchitoches, Louisiana, 71457
Kenneth Perego
- Available
NYU Langone Health
New York, New York, 10016
Anthony Corcoran, MS,MD, FACS
- Available
The Urology Center, P. C. D/B/A/ UroHealth Partners
Omaha, Nebraska, 68114
Shelby Nelson, 402-399-7893, snelson@adultpediatricuro.com
Judson Davies, MD
- Available
Capital Health Urology
Pennington, New Jersey, 08534
Neena Shetty, 609-394-4130, nshetty@capitalhealth.org
Eric Mayer, MD
- Available
Department of Urology, Jefferson Einstein Hospital
Philadelphia, Pennsylvania, 19141
Christine Hubert, 609-941-1162, christine.hubert@jefferson.edu
Edouard Trabulsi, MD
- Available
Mayo Clinic
Phoenix, Arizona, 85054
Darwin Soriano, 480-574-2940, Soriano.Darwin@mayo.edu
Mark Tyson, MD
- Available
Virginia Urology
Richmond, Virginia, 23235
Jordan N Moore, 804-288-2785 ext. 7808, jnmoore@uro.com
Charles Seabury, MD
- Available
The Urology Place
San Antonio, Texas, 78240
210-617-3670
Naveen Kella, MD
- Available
Saint John's Cancer Institute (Providence)
Santa Monica, California, 90404
Jazmin Ledesma, 310-582-7427, jazmin.ledesma@providence.org
Jennifer Linehan, MD
- Available
Sebring Urology Center
Sebring, Florida, 33870
Anthony Arciola, MD
- Available
Willis Knighton Urologic Oncology at Pierremont
Shreveport, Louisiana, 71115
David T Price, MD
- Available
Advanced Urology Skokie
Skokie, Illinois, 60077
Lev Elterman
- Available
Pioneer Valley Urology, P.C.
Springfield, Massachusetts, 01107
Michael Zavaski
- Available
SUNY Upstate Medical University
Syracuse, New York, 13210
Nicholas Carusone, 315-464-5296, carusonn@upstate.edu
Joseph Jacob, MD
- Available
Florida Urology Partners
Tampa, Florida, 33615
Osvaldo Padron, MD
- Available
Center for Neurosciences
Tucson, Arizona, 85718
Crystal Placencia, 520-529-5234, Cplacencia@neurotucson.com
Karen Wheeler, MD
- Available
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010
Hiwot Guebre-Xabihner, 202-877-9386, Hiwot.Guebre-Xabiher@medstar.net
Lambros Stamatakis, MD
- Available
Comprehensive Urology
Waterford, Michigan, 48328
Kenneth Lim, DO
- Available
Wichita Urology
Wichita, Kansas, 67226
Tyler Gentry, 316-636-6163, tgentry@wichitaurology.com
Philippe Nabbout, MD
- Available
Valley Health Urology
Winchester, Virginia, 22601
Megan Lloyd, 540-667-1712, mlloyd2@valleyhealthlink.com
Jeremy Kelley, MD
- Available
Minnesota Urology
Woodbury, Minnesota, 55125
Alex Alchev, 651-999-6800, aalchev@mnurology.com
Aaron Milbank, MD
- Available
Center for Urologic Care of Berks County
Wyomissing, Pennsylvania, 19610
Shawn White, MD
About this study
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are ineligible to participate in a clinical trial using rMBCG, or for other reasons cannot participate (eg, geographically unable to access a study site).
- Conditions
- NMIBC
- Being tested
- rMBCG
- Medical subject headings
- Non-Muscle Invasive Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rMBCGBiological
1-19.2e8 colony-forming units (CFU) of rMBCG
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NMIBCStudies of the same condition, open and under way.
- More trials run by ImmunityBio, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- ImmunityBio, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06810141
- Sponsor's protocol ID
- ResQ132EX-NMIBC
- Status last verified
- Jan 2026
- First submitted
- 30 Jan 2025
- Last updated
- 14 May 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
- ClinicalTrials.gov ID
- NCT06810141
- Acronym / sponsor ID
- ResQ132EX-NMIBC
- Conditions
- NMIBC
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- ImmunityBio, Inc.Industry (pharma, biotech, devices)
- First posted
- 5 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are ineligible to participate in a clinical trial using rMBCG, or for other reasons cannot participate (eg, geographically unable to access a study site).
Study design
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Participants must meet the inclusion criteria and contraindications determined by the standards of their institution per the TICE BCG label. In BCG naïve subjects with NMIBC, enrollment should occur only if TICE BCG is unavailable.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rMBCG1-19.2e8 colony-forming units (CFU) of rMBCG | Biological | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
Related trials for NMIBC
RecruitingPhase 1
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Non-muscle Invasive Bladder Cancer
Recruiting
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer (NMIBC)
Active, not recruitingPhase 3
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Non-Muscle Invasive Bladder Neoplasms
RecruitingPhase 2
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle-Invasive Bladder Cancer (NMIBC)
RecruitingPhase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
66 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing rMBCG in people with NMIBC, run by ImmunityBio, Inc. at 66 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 66 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jayson Garmizo (310-912-2230, jayson.garmizo@immunitybio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.